Novel Nitrile Peptidomimetics for Treating COVID-19

Novel Nitrile Peptidomimetics for Treating COVID-19

ACS Medicinal Chemistry Letters

10.1021/acsmedchemlett.2c00030

http://dx.doi.org/10.1021/acsmedchemlett.2c00030

C. S. Brian Chia

Biochemistry, Organic Chemistry, drug discovery

03 February 2022

Chia, C. S. B. (2022). Novel Nitrile Peptidomimetics for Treating COVID-19. ACS Medicinal Chemistry Letters, 13(3), 330–331. https://doi.org/10.1021/acsmedchemlett.2c00030

COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Nirmatrelvir, to treat patients with mild-to-moderate COVID-19. This patent review reveals the structure–activity relationship of key inhibitors described in the patent WO 2021/250648 A1.

Publisher Copyright

This research is supported by core funding from: Experimental Drug Development Centre
Grant Reference no. : NRF2021-IE-IECF-001

This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Medicinal Chemistry Letters copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see doi.org/10.1021/acsmedchemlett.2c00030

https://oar.a-star.edu.sg/communities-collections/articles/19031

1948-5875

Experimental Drug Development Centre